Further, the progression of HFD-induced overweight/obesity and the metabolic syndrome are both attenuated by pharmacological or genetic reduction of plasma insulin responses to feeding or by inhibition of insulin signaling, without evident changes in net daily energy intake (11–15). The gene discussed is INS; the disease is obesity disorder.